Member Exclusive

CRISPR-Cas9 approach identifies new drug targets to aid cancer immunotherapy

A novel CRISPR-Cas9 screening method developed by a team at Dana-Farber/Boston Children’s Cancer and Blood Disorders Center (Boston, MA, USA) has revealed new drug targets that could potentially enhance the effectiveness of PD-1 checkpoint inhibitors, a promising class of cancer immunotherapeutics.

Go to the profile of Peter Brown
Aug 03, 2017
0
0

Please sign in or register for FREE

Register to MedChemNet – the medicinal chemistry network

MedChemNet is a communal space where industry and academic professionals can come together to discuss the latest research and developments, share thoughts and opinions, and build valuable international relationships.

Register

No comments yet.